Boehringer Ingelheim has partnered with GoodRx to offer the drugmaker’s Humira biosimilar, adalimumab-adbm, in another move by manufacturers to try and wedge themselves into a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.